Aldrich Melissa B, Guilliod Renie, Fife Caroline E, Maus Erik A, Smith Latisha, Rasmussen John C, Sevick-Muraca Eva M
Biomed Opt Express. 2012 Jun 1;3(6):1256-65. doi: 10.1364/BOE.3.001256. Epub 2012 May 3.
Current treatment of unilateral breast cancer-related lymphedema (BCRL) is only directed to the afflicted arm. Near-infrared fluorescent imaging (NIRF) of arm lymphatic vessel architecture and function in BCRL and control subjects revealed a trend of increased lymphatic abnormalities in both the afflicted and unafflicted arms with increasing time after lymphedema onset. These pilot results show that BCRL may progress to affect the clinically "normal" arm, and suggest that cancer-related lymphedema may become a systemic, rather than local, malady. These findings support further study to understand the etiology of cancer-related lymphedema and lead to better diagnostics and therapeutics directed to the systemic lymphatic system.
目前,单侧乳腺癌相关淋巴水肿(BCRL)的治疗仅针对患侧手臂。对BCRL患者和对照对象的手臂淋巴管结构与功能进行的近红外荧光成像(NIRF)显示,随着淋巴水肿发作后时间的增加,患侧和未患侧手臂的淋巴异常均有增加的趋势。这些初步结果表明,BCRL可能会进展至影响临床上“正常”的手臂,并提示癌症相关淋巴水肿可能成为一种全身性而非局部性疾病。这些发现支持进一步开展研究,以了解癌症相关淋巴水肿的病因,并促成针对全身淋巴系统的更好诊断与治疗方法。